Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Common Equity (2016 - 2025)

Plus Therapeutics has reported Common Equity over the past 16 years, most recently at $4.0 million for Q4 2025.

  • Quarterly Common Equity rose 144.65% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 144.65% year-over-year, with the annual reading at $4.0 million for FY2025, 144.65% up from the prior year.
  • Common Equity was $4.0 million for Q4 2025 at Plus Therapeutics, down from $5.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $14.8 million in Q3 2021 and troughed at -$23.6 million in Q1 2025.
  • The 5-year median for Common Equity is $3.5 million (2025), against an average of $2.9 million.
  • Year-over-year, Common Equity skyrocketed 11091.76% in 2021 and then crashed 563.87% in 2024.
  • A 5-year view of Common Equity shows it stood at $10.8 million in 2021, then tumbled by 40.52% to $6.4 million in 2022, then tumbled by 120.92% to -$1.3 million in 2023, then crashed by 563.87% to -$8.9 million in 2024, then skyrocketed by 144.65% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Common Equity are $4.0 million (Q4 2025), $5.1 million (Q3 2025), and $3.0 million (Q2 2025).